![Steven J. Roy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steven J. Roy
Vorstandsvorsitzender bei VetDC, Inc.
Profil
Steven J.
Roy is currently the President, Chief Executive Officer & Director at VetDC, Inc. Prior to this, he worked as the Director-Licensing & Alliance Management at Amgen, Inc. from 1994 to 2007 and as a Laboratory Supervisor at Ligand Pharmaceuticals, Inc. from 1988 to 1992.
He received his undergraduate degree from the University of California San Diego and his MBA from the University of Michigan.
Aktive Positionen von Steven J. Roy
Unternehmen | Position | Beginn |
---|---|---|
VetDC, Inc.
![]() VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Vorstandsvorsitzender | 01.01.2010 |
Ehemalige bekannte Positionen von Steven J. Roy
Unternehmen | Position | Ende |
---|---|---|
AMGEN INC. | Corporate Officer/Principal | - |
LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Ausbildung von Steven J. Roy
University of California San Diego | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMGEN INC. | Health Technology |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
Private Unternehmen | 1 |
---|---|
VetDC, Inc.
![]() VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Process Industries |